Deferred treatment of localized prostate cancer in the elderly: The impact of the age and stage at the time of diagnosis on the treatment decision

BJU International

Volumn 85, Issue 6, 2000, Pages 699-704

  Neulander, E Z ^a   Duncan, R C ^b   Tiguert, R ^a   Posey, J T ^a   Soloway, M S ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Age; External beam radiation; Gleason score; Hormonal therapy; Prostate cancer; Serum PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADOLESCENT; ADULT; AGE; ARTICLE; CANCER STAGING; DISEASE COURSE; FOLLOW UP; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MULTIVARIATE ANALYSIS; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT PLANNING;

AGE FACTORS; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM STAGING; PATIENT SELECTION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0034109362     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2000.00569.x     Document Type: Article

References (22)

1. 1 Roberts RO, Bergstralh EJ, Katusic SK, Lieber MM, Jacobsen S. Decline of prostate cancer mortality from 1980 to 1997 and an update on incidence trends in Olmsted County, Minnesota. J Urol 1999; 161: 529-33
2. 2 Kirk D. Prostate cancer in elderly. Eur J Surg Oncol 1998; 24: 379-83
3. 3 Palmer JS, Chodak GW. Defining the role of surveillance in the management of localized prostate cancer. Urol Clin N Am 1996; 23: 551-6
4. 4 Studer UE. Radical prostatectomy or deferred treatment. Sem Surg Oncol 1995; 11: 46-9
5. 5 Brasso K, Friis S, Iversen P et al. Mortality of patients with clinically localized prostate cancer treated with observation for 10 years or longer: a population based registry study. J Urol 1999; 161: 524-8
6. 6 Steinberg GD, Bales GT, Brendler CB. An analysis of watchful waiting for clinically localized prostate cancer. J Urol 1998; 159: 1431-6
7. 7 Johansson JE, Adami HO, Andersson SO, Bergstrom R, Holmberg L, Krusemo UB. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 1992; 267: 2191-6
8. 8 Chodak GW, Thisted RA, Gerber GS et al. results of conservative management of clinically localized prostate cancer. New Engl J Med 1994; 330: 242-8
9. 9 Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995; 274: 626-31
10. 10 Thompson IM. How has stage migration affected our concept of the natural history of untreated prostate cancer. AUA Update Series 1998; 17: 194-9
11. 11 Graversen PH, Nielsen KT, Gasser TC et al. Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer. Urology 1990; 36: 493-8
12. 12 Corral DA, Bahnson RR. Survival of men with clinically localized prostate cancer detected in the eighth decade of life. J Urol 1994; 151: 1326-9
13. 13 Chodak GW. The role of watchful waiting in the management of localized prostate cancer. J Urol 1994; 152: 1766-8
14. 14 Gronberg H, Damber JE, Jonsson H, Lenner P. Patient age as a prognostic factor in prostate cancer. J Urol 1994; 152: 892-5
15. 15 The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostate cancer. Br J Urol 1997; 79: 235-46
16. 16 Jonler M, Nielsen OS, Wolf H. Urinary symptoms, potency and quality of life in patients with localized prostate cancer followed up with deferred treatment. Urology 1998; 52: 1055-63
17. 17 Mohler JL, Williams BT, Freeman JA. Expectant management as an option for men with stage Tlc prostate cancer: a preliminary study. World J Urol 1997; 15: 364-8
18. 18 Schmid HP. Tumor markers in patients on deferred treatment: Prostate specific antigen doubling times. Cancer Surveys 1995; 23: 157-67
19. 19 Schmid HP, McNeal J, Stamey TA. Observations on the doubling time of prostate cancer. Cancer 1993; 71: 2031-40
20. 20 Nam RK, Klotz LH, Jewett MAS, Danjoux C, Trachtenberg J. Prostate specific antigen velocity as a measure of the natural history of prostate cancer: defining a 'rapid riser' subset. Br J Urol 1998; 81: 100-4
21. 21 Bangma CH. Hop WCJ, Schroder FH. Serial prostate specific antigen measurements and progression in untreated confined (stages T0 - 3NxM0, grades 1-3) carcinoma of the prostate. J Urol 1995; 154: 1403-6
22. 22 Carter BH, Epstein J, Partin AW. Influence of age and prostate specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. Urology 1999; 53: 126-30